Alvogen, Inc. announced FDA approval for its Abbreviated New Drug Application (ANDA202116) to manufacture generic oxycodone hydrochloride tablets, signaling the company’s strategic entry into the highly competitive oral opioid market. This clearance positions Alvogen to capitalize on generic demand within the pain management sector, potentially influencing the pricing strategies and market share of established competitors.